Goldman Sachs Invests in Aragen Life Sciences
19.5.2021 12:53:00 EEST | Business Wire | Press release
Aragen Life Sciences (“Aragen”), formerly known as GVK Biosciences and a leading contract research organization (CRO), announced today that Goldman Sachs, an active investor in India, has taken a significant minority stake in the company by acquiring shares previously held by ChrysCapital and other existing shareholders.
Aragen is a leading provider of outsourced discovery, development, and manufacturing services across both large and small molecule platforms. The company serves a worldwide customer base which spans to the United States, Europe, and Japan. Aragen has demonstrated strong organic growth on the back of deep domain expertise, strong global delivery capabilities, and partnerships with global biopharmaceutical and biotech clients.
“We believe this new investment at this important juncture in our company’s development underscores the tremendous opportunity ahead. Working with Goldman Sachs, we are well-positioned to address the opportunities in front of us to become a leading, global player with comprehensive end-to-end solutions for drug discovery and development,” said Manni Kantipudi, CEO of Aragen Life Sciences. “For more than five years, ChrysCapital has been a trusted investment partner. Following their successful exit, we are pleased to now enter a new phase in our continued evolution.”
“Aragen is well-positioned to benefit from the secular trend of increased outsourcing by the life sciences industry. With a clear value creation plan in place, we look forward to closely working with the management and shareholders of Aragen,” said Rajat Sood, a managing director at Goldman Sachs Asset Management. “Goldman Sachs is actively seeking to invest and foster leading, national champions of India who are building companies of a global scale.”
“As an experienced global investor in the healthcare sector and India, we look forward to leveraging our worldwide network and experience to help expand Aragen’s portfolio of differentiated offerings and client base to accelerate the company’s growth,” said Michael Bruun, a managing director at Goldman Sachs Asset Management.
Raghav Ramdev, Managing Director at ChrysCapital said, “We are proud to have seen Aragen grow and scale from providing discovery services to successfully expand into development and manufacturing, as well as biologics. It has evolved into an industry leader with a strong base of innovator clients.”
Goldman Sachs is an active investor in India, deploying more than $3.6 billion in capital since 2006. Previous investments in Indian healthcare include Biocon Biologics, BPL Medical Technologies, CyteCare Hospitals, Max India and Nova Medical Centers.
Jefferies, Dimensions, and Shardul Amarchand Mangaldas & Co advised company, existing shareholders and ChrysCapital. Trilegal, Herbert Smith Freehills, and Deloitte advised Goldman Sachs.
About Aragen Life Sciences
Aragen Life Sciences Pvt Ltd (“Aragen”) is a leader in discovery, development and manufacturing solutions. We offer differentiated contract research organization (CRO) and contract development and manufacturing organization (CDMO) solutions for small and large molecules. Through a presence across seven sites in India and overseas. Aragen employees over 3,000 professionals globally and serves more than 450 life sciences customers across biotech and large cap companies.
About Goldman Sachs Asset Management
Goldman Sachs is one of the world’s leading investors in alternative investments. With over 30 years of experience, we invest in the full spectrum of alternatives, including private equity, growth equity, credit, real estate, infrastructure, ESG, and absolute-return strategies. Our clients access these solutions through our direct proprietary strategies, customized strategic partnerships, and open-architecture programs. Our alternative investment teams represent over 1,000 professionals, across 50 offices around the world. We leverage the depth and breadth of global relationships across Goldman Sachs to identify investment opportunities, drawing on our firm-wide capital market insights, industry research, and risk management platforms. We extend these capabilities to the world’s leading pension plans, sovereign wealth funds, governments, financial institutions, endowments, foundations, family offices and individuals, for which we invest or advise on over $350 billion of alternative investments.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005419/en/
Contact information
Media Contacts:
Aragen Life Sciences (Formerly known as GVK Biosciences): Sarat Patanaik, +91 95732 80064, sarat.patanaik@gvkbio.com
Goldman Sachs: Danika D’Souza, +91 98335 83779, DDSouza@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 22:10:00 EEST | Press release
Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build the central nervous system of enterprise security, giving organizations unified visibility and control over their endpoints. During his prior tenure as CEO from 201
Perma-Pipe Secures More Than $67 Million in New Orders in the Second Quarter of 202620.8.2026 20:02:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in engineered piping and corrosion protection solutions, today announced that the Company secured more than $67 million in new orders during the second quarter of fiscal 2026, representing strong demand across its strategically important end-markets and geographies. The orders further strengthen Perma-Pipe's backlog and provide increased visibility into future revenue growth. The Company's backlog remains well diversified across geographies, customers and end-markets. The Company continued to see strong demand across its core Oil & Gas and infrastructure markets, while also securing important new business in emerging applications, including advanced leak detection and monitoring solutions. During the quarter, Perma-Pipe secured sizable Oil & Gas awards in both MENA and Canada, reinforcing the Company's position as a trusted supplier to customers undertaking significant energy infrastructure investments. The Company
Impartner Launches the First CPQ Built for Partners20.8.2026 16:00:00 EEST | Press release
Impartner, the leading partner revenue orchestration platform, today announced the launch ofImpartner CPQ, giving partners a direct path to create and advance quotes within the Impartner PRM platform. The new capability enables faster movement from opportunity to submission while giving vendors control over the rules, products, pricing, and approvals that govern each transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820479441/en/ Give partners a faster path from opportunity to quote with Impartner's CPQ. For many partnership programs, quoting remains a largely manual process. Partners often depend on vendor sales teams to prepare quotes because traditional CPQ systems are designed primarily for direct sellers or require additional licensing for external users. The result is a slower path from opportunity to revenue, increased administrative work for channel teams, and a partner experience that can limit the impa
Scientist.com Expands R&D Platform Capabilities with SciSure’s Integrated LabOps Inventory and Compliance Services20.8.2026 15:55:00 EEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, today announced an expansion of its platform capabilities through an integration with SciSure’s lab management and EHS compliance tools. The partnership gives biopharma organizations a more unified workflow connecting scientific procurement directly with laboratory operations. “By bringing SciSure’s inventory management, safety, and compliance capabilities into the Scientist.com ecosystem, we are closing the gap between sourcing reagents and safely managing them in the laboratory,” said Jon Zibell, VP of Global Alliances at SciSure. “Together, our platforms connect product information, safety checks, and inventory management, giving research, lab operations, and EHS teams greater visibility from purchase request through disposal.” The integration connects procurement, safety, inventory, and compliance in a single connected workflow. SciSure enriches Scientist.com’s unified
NETFORCE Accelerates Its U.S. Industrial Expansion as a New Intermediate-Force Market Takes Shape20.8.2026 15:23:00 EEST | Press release
For the first time, major U.S. federal agencies are beginning to structure procurement around a new category of intermediate-force equipment, giving officers an additional option between verbal presence and higher levels of force. NETFORCE believes companies establishing themselves at this early stage will benefit from a significant first-mover advantage as this category expands nationwide. This is precisely the market NETFORCE anticipated years ago, having invested heavily in research, industrialization and international intellectual property well before the category attracted attention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820951658/en/ COPYRIGHT NETFORCE NETFORCE enters the U.S. market backed by two granted and active U.S. patents — US 11,236,973 B2 (granted 2022, protected through 2038) and US 12,222,193 B2 (granted 2025, protected through 2041). Together with the E-StunGlove® trademark, these assets form pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom